MXPA04002147A - Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1. - Google Patents

Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1.

Info

Publication number
MXPA04002147A
MXPA04002147A MXPA04002147A MXPA04002147A MXPA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A
Authority
MX
Mexico
Prior art keywords
cells
methods
response
compositions
type
Prior art date
Application number
MXPA04002147A
Other languages
English (en)
Spanish (es)
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of MXPA04002147A publication Critical patent/MXPA04002147A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
MXPA04002147A 2001-09-06 2002-09-06 Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1. MXPA04002147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (1)

Publication Number Publication Date
MXPA04002147A true MXPA04002147A (es) 2005-03-07

Family

ID=32654226

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002147A MXPA04002147A (es) 2001-09-06 2002-09-06 Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1.

Country Status (17)

Country Link
US (2) US20050059151A1 (enExample)
EP (3) EP1441591B1 (enExample)
JP (3) JP2005505270A (enExample)
KR (3) KR20110081341A (enExample)
CN (2) CN1636229B (enExample)
AU (1) AU2008221592B2 (enExample)
BR (1) BRPI0212545B8 (enExample)
CA (1) CA2459713C (enExample)
DK (2) DK1441591T3 (enExample)
ES (2) ES2766299T3 (enExample)
IL (3) IL160720A0 (enExample)
MX (1) MXPA04002147A (enExample)
NO (2) NO338147B1 (enExample)
NZ (1) NZ531530A (enExample)
PL (1) PL372098A1 (enExample)
PT (2) PT2322603T (enExample)
WO (1) WO2003022215A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
ATE420946T1 (de) * 2003-02-27 2009-01-15 Northwest Biotherapeutics Inc Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
EP1775343A4 (en) 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
EP1957634A4 (en) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
CA2863653A1 (en) * 2012-02-02 2013-08-08 California Stem Cell, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
EP2857498B1 (en) * 2012-05-31 2018-04-25 JW Creagene Inc. Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US20140065173A1 (en) * 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
WO2014093454A1 (en) 2012-12-12 2014-06-19 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US9792656B1 (en) 2014-05-20 2017-10-17 State Farm Mutual Automobile Insurance Company Fault determination with autonomous feature use monitoring
US9783159B1 (en) 2014-07-21 2017-10-10 State Farm Mutual Automobile Insurance Company Methods of theft prevention or mitigation
US10431018B1 (en) 2014-11-13 2019-10-01 State Farm Mutual Automobile Insurance Company Autonomous vehicle operating status assessment
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
MX2018000056A (es) * 2015-06-30 2018-05-28 Northwest Biotherapeutics Inc Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
US20210258486A1 (en) 2015-08-28 2021-08-19 State Farm Mutual Automobile Insurance Company Electric vehicle battery conservation
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10386192B1 (en) 2016-01-22 2019-08-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle routing
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
MX2022004186A (es) * 2019-10-07 2022-07-19 Northwest Biotherapeutics Inc Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
BR9610802A (pt) * 1995-10-04 1999-07-13 Immunex Corp Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
DK1292321T3 (da) * 2000-05-12 2012-01-30 Northwest Biotherapeutics Inc Fremgangsmåde til at forøge klasse 1 præsentation af exogene antigener gennem humane dendritiske celler
ES2254527T3 (es) * 2001-01-15 2006-06-16 I.D.M. Immuno-Designed Molecules Metodo para la preparacion de suspensiones de particulas submicronicas de agentes farmaceuticos.
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
BRPI0212545B8 (pt) 2021-05-25
WO2003022215A2 (en) 2003-03-20
NO20151562A1 (no) 2015-11-16
CN102973928A (zh) 2013-03-20
BRPI0212545B1 (pt) 2019-12-03
PT1441591T (pt) 2016-10-06
CN102973928B (zh) 2019-03-15
EP2322603A1 (en) 2011-05-18
EP2322603B1 (en) 2019-10-16
JP2011188872A (ja) 2011-09-29
NZ531530A (en) 2007-01-26
IL160720A0 (en) 2004-08-31
CA2459713C (en) 2015-08-18
PL372098A1 (en) 2005-07-11
CA2459713A1 (en) 2003-03-20
PT2322603T (pt) 2020-01-21
AU2008221592A1 (en) 2008-10-16
CN1636229A (zh) 2005-07-06
JP2005505270A (ja) 2005-02-24
EP1441591A4 (en) 2006-06-07
IL219266A (en) 2014-02-27
JP6114768B2 (ja) 2017-04-12
WO2003022215A3 (en) 2003-11-13
NO338147B1 (no) 2016-08-01
EP1441591B1 (en) 2016-06-29
US20050059151A1 (en) 2005-03-17
KR20140116544A (ko) 2014-10-02
HK1079989A1 (en) 2006-04-21
EP3653055A1 (en) 2020-05-20
NO20040965L (no) 2004-04-23
BR0212545A (pt) 2005-01-18
AU2008221592B2 (en) 2012-12-20
KR101803702B1 (ko) 2017-12-01
US20080254064A1 (en) 2008-10-16
IL160720A (en) 2012-05-31
JP2015107133A (ja) 2015-06-11
ES2766299T3 (es) 2020-06-12
DK1441591T3 (en) 2017-05-22
ES2598109T3 (es) 2017-01-25
KR20050027163A (ko) 2005-03-17
KR20110081341A (ko) 2011-07-13
BRPI0212545A8 (pt) 2019-10-15
DK2322603T3 (da) 2020-01-27
CN1636229B (zh) 2012-12-19
JP5777956B2 (ja) 2015-09-16
EP1441591A2 (en) 2004-08-04
IL219266A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2003022215A3 (en) Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
AU3877500A (en) Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
IL166309A0 (en) Preparation of 1h-imidazoÄ4,5-cÜquinolin-4-amines via 1h-imidazoÄ4,5-cÜquinolin-4-phthalimide intermediates
BG104511A (en) Spheroids, preparation method and pharmaceutical compositions
NZ532665A (en) Neisseria meningitidis antigens and compositions
CA2396250A1 (en) Mutant apre promoter
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
IL117425A0 (en) Receptor activation by gas6
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
JO2410B1 (en) 6. Replaced pyrido-pyrimidines
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
MXPA04011071A (es) Analisis de calidad para celulas que presentan antigenos.
EP1288931A3 (en) Optical recording article
IL151678A (en) Method for producing asymmetrical 4,6-bis (aryloxy) pyrimidine derivatives
IN187760B (enExample)
AU5334301A (en) Human ovarian mesothelial cells and methods of isolation and uses thereof
AU4925200A (en) Oral composition containing perlite
YU62800A (sh) Postupak za proizvodnju r-(+)-6- karboksamido-3n-metilamino- 1,2,3,4-tetrahidrokarbazola
WO2003020893A3 (en) New adenovirus type 7 vectors
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
AU2002222695A1 (en) Novel 4'-demethyl-4'-o-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same
MY130958A (en) Compositions comprising higher diamondoids and processes for their separation
UA66859C2 (uk) Спосіб стереохімічно контрольованого одержання ізомерно чистих високозаміщених азациклічних сполук
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
AU2910800A (en) Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines

Legal Events

Date Code Title Description
FG Grant or registration